A high serum triglyceride (TG) concentration is associated with an increased serum concentration of small, dense low-density lipoprotein (LDL). To further characterize the hypertriglyceridemic condition, we examined sera from 240 subjects for small, dense LDL using non-denaturing polyacrylamide gradient gel electrophoresis. We focused on determining the frequency of the pattern B, which is characterized by a higher proportion of small, dense LDL, among hypertriglyceridemic individuals. The subjects were divided into four groups: a control group (TG ≤ 1.65 mmol/l, high-density lipoprotein cholesterol (HDL-C) ≥1.17 mmol/l; n = 71), a high TG group (TG > 1.65 mmol/l, HDL-C ≥ 1.17 mmol/l; n = 36), a group with high TG and low HDL-C (TG > 1.65 mmol/l, HDL-C ≤ 0.91 mmol/l; n = 106), and a low HDL-C group (TG ≤ 1.65 mmol/l, HDL-C ≤ 0.91 mmol/l; n = 27). We found that pattern B occurs at a high frequency mainly in individuals with high TG and low HDL-C levels. We also observed an increased percentage of LDL within the 20.0 nm to 25.5 nm particle diameter range in this group. Analysis of the lipoprotein lipase gene in this group showed that some mutations seem to be associated with small, dense LDL, resulting in LDL pattern B.
Introduction
Low-density lipoprotein (LDL) particles are major cholesterol carriers in plasma and are considered the most atherogenic lipoprotein fraction. LDL consists of particles of different composition, size, density distribution, and atherogenic effect (1) (2) (3) . Using non-denaturing 2-16% gradient gel electrophoresis, Austin and colleagues (3) developed an analytical procedure for measuring heterogeneity of LDL size, by which LDL can be described according to two distinct phenotypes, pattern A and pattern B. Pattern A phenotype is characterized mainly by large LDL particles (≥ 25.5 nm in diameter) whereas pattern B phenotype is characterized to a high proportion of small, dense LDL (< 25.5 nm) particles. There is evidence (4) that pattern B phenotype is frequently seen in patients with coronary heart disease (CHD). Small, dense LDL has been noted as a predictive marker for increased risk of CHD (5) . In general, the serum content of small, dense LDL is positively correlated with increased serum levels of both triglyceride (TG) and apolipoprotein B (apo B) and negatively correlated with decreased serum levels of high-density lipoprotein cholesterol (HDL-C) and apolipoprotein A-I (apo A-I) (6) . The mechanism for producing small, dense LDL remains unclear. Linkage analysis has provided statistically significant evidence for genetic linkage of small, dense LDL size to the lipoprotein lipase (LPL) gene locus in families with a structural LPL gene mutation (7) .
The aim of this study was to investigate the occurrence of the pattern B phenotype in relation to hypertriglyceridemia. We also quantitated the heterogeneity of LDL particles in serum using densitometry to assess heterogeneity more precisely. Moreover, we analyzed the LPL gene structure to determine whether there is association between LPL gene mutations and the pattern B phenotype.
Subjects, Materials and Methods

Subjects
Two hundred and forty subjects were selected for this study from patients in which fasting plasma lipids were examined at the Hamamatsu University School of Medicine Hospital. Subjects included 169 persons with elevated TG (>1.65 mmol/l), and/or low HDL-C ( ≤ 0.91 mmol/l), and 71 persons who were not taking lipid-lowering medications and had normal lipid profiles.
These subjects were divided into four groups according to the following lipid profiles: serum TG ≤ 1.65 mmol/l and HDL-C ≥ 1.17 mmol/ (control group, n = 71); serum TG >1.65 mmol/l and HDL-C ≥ 1.17 mmol/l (group 1, n=36); serum TG > 1.65 mmol/l and HDL-C ≤ 0.91 mmol/l (group 2, n = 106); serum TG ≤ 1.65 mmol/l and HDL-C ≤ 0.91 mmol/l (group 3, n = 27). Five subjects in group 1 and 19 subjects in group 2 were taking lipid-lowing medication.
Lipids and lipoproteins analysis
Sera for assaying lipids and lipoproteins were used within 1 week after blood samples were drawn. Serum total cholesterol (TC), HDL-C, and TG concentrations were measured by enzymatic methods using commercial kits (Kyowa Medex Co, Ltd, Tokyo, Japan). Serum LDL cholesterol (LDL-C) was also determined using a kit and protocol supplied by the manufacturer (Daiichi Pure Chemicals Co, Ltd, Tokyo, Japan). Serum apo A-I and apo B concentrations were measured by the turbidimetric immunoassay technique (Daiichi Pure Chemicals). The intra-and interassay CV values were < 3% and < 1.4%, respectively for TG, < 3% and < 1.1%, respectively for TC, < 5% and < 1.6%, respectively for HDL-C, < 3% and <1.6%, respectively for LDL-C, < 5% and <1.9%, respectively for apo A-I, and < 5% and 2.6%, respectively for apo B.
LDL size determination
Serum samples were stored at -80 °C after being added into 25% sucrose and 1.3 mM EDTA 2 Na for stabilizing sample until analysis. Analysis of molecular LDL heterogeneity was carried out according to the procedure of Krauss and Burke (8) with some modifications. The electrophoresis unit was filled with fresh buffer consisting of 0.09 M Tris-HCl, 0.08 M boric acid, and 3.0 mM Na 2 EDTA, pH 8.3. Serum sample was diluted 5-fold in final loading buffer composed of concentrations of 25% sucrose, 0.12 mM EDTA 2 Na and 0.12 mM bromophenol blue. After pre-electrophoresis of 2-15% polyacrylamide gradient gels (Daiichi Pure Chemicals) at 4 °C and 125 V for 15 min, 5 µl of prepared serum sample was loaded into the gel. Electrophoresis was carried out at 4 °C for the following periods and voltages: (1) 15 min at 25 V, (2)15 min at 70 V, and (3) 24 h at 125 V. The gels were stained with Sudan Black B lipid stain (Daiichi Pure Chemicals) for 3 h at room temperature after fixation in 40% methanol and 10% ethylene glycol (Solution A) for 30 min. The gels were destained in Solution A and dried. As a reference standard, control serum was prepared from a healthy subject. LDL size in control serum was obtained using a standard curve (9, 10) . This serum was stored at -80 °C in small aliquots after being added to 25% sucrose and 1.3 mM EDTA 2 Na. It was subsequently thawed when needed and run on two lanes of each gel. Each gel was scanned by a densitometer interfaced with a computer. The migration distance of each LDL peak for each sample was determined from the densitometric curves against the peak of the control serum. Thus, the migration distance of each sample could be expressed as the migration distance relative to each peak in control serum and converted to LDL particle diameters. The highest LDL peak was used to define the diameter of the predominant LDL particles. The intra-run and inter-run CV values for LDL size were < 0.7% and < 0.9%, respectively. Furthermore, LDL phenotypes were classified based on the size of the predominant particles (3). The quantities of total LDL were determined by measuring the area of LDL in the density scan of a diameter between 20.0 nm and 30.0 nm. Similarly, a diameter between 20 nm and 25.5 nm was calculated as the area of small, dense LDL. The percentage of small, dense LDL in each sample, expressed as % area, was calculated from the area of small, dense LDL divided by the total LDL area.
Quantification of LPL mass
Serum samples were collected and stored at -80 °C. Serum pre-heparin LPL mass was measured with a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Daiichi Pure Chemicals) according to the method reported by Saito et al. (11) .
DNA analysis
Blood was collected in tubes containing 0.1% EDTA and stored at -80 °C. Genomic DNA was extracted from leukocytes after erythrocyte lysis and resolved in 10 mM Tris-HCl buffer, 1 mM EDTA 2 Na, pH 7.0, and stored at -20 °C. Oligonucleotide primer sequences for amplifying LPL gene exons 1, 2, 3, 4, 5, 6, 9, and 10 were obtained from Gotoda et al. (12) . Exon 7 and 8 primers were designed according to sequences reported previously (13) and were as follows: exon 7, sense 5'-GATTGATCAACATGTTCGAA-3' and antisense 5'-GGGACTG-GTGCCATGATGA-3'; exon 8, sense 5'-GATCTCTATAACTAAC-CAAAA-3' and antisense 5'-TGGGG GTCTAAAGTGAAGGA-3. Target DNA sequences were amplified in a 50 µl reaction volume containing 0.25 µg of genomic DNA, 0.25 pmol of each oligonucleotide primer, 200 µM dATP, dCTP, dGTP, and dTTP, 1.25 U of Taq DNA polymerase (Boehringer Mannheim GmbH, Mannheim, Germany), and reaction buffer (10 mM Tris-HCl, 50 mM KCl; 1.5 mM MgCl 2 ). Samples were denatured at 96 °C for 5 min, and 35 cycles of polymerase chain reaction (PCR) were performed with a GeneAmp PCR System 9600 (ABI Perkin-Elmer, Norwalk, CT, USA). Each cycle consisted of denaturation for 1 min at 94 °C, annealing for 1 min at 50 °C (exon 8, 10), 52 °C (exon 7), 54 °C (exon 3, 4), 56 °C (exon 2, 10), 58 °C (exon 1, 9), 62 °C (exon 5), or 63 °C (exon 6) and extension for 2 min at 72 °C.
PCR single-strand conformation polymorphism (PCR-SSCP) analysis was performed as described previously (14) . PCR products showing an abnormal pattern were purified. The purified DNA fragments were directly sequenced with the 373A DNA Sequencing System (ABI Perkin-Elmer, USA) with a DNA Sequencing kit (ABI Perkin-Elmer, USA). The mutation was confirmed by PCR restriction fragment length polymorphism (PCR-RFLP) (15) or mismatched PCR-RFLP (16) .
Statistical analysis
Statistical computation was performed with the Statistical Analysis System (SAS institute Inc., USA, version 6.08). Original individual plasma lipid levels were adjusted by two-way analysis of variance for age. There were three groups classified by age: 49 years and below, 50-59 years, 60 years and above. Least-squares means (LSM), their standard errors, and the corresponding probabilities were obtained by the GLM Procedure. The original lipid data in two subgroups of patients (group 2; men with and without LPL mutations) were also adjusted for age. The main effects on covariance were included in each model. The interactions of age on each lipid variable were not found between groups or subgroups. Correlation coefficients were used to determine the relation between LDL size and other variables. Differences in pattern A and pattern B distributions were compared by chi-square and Fisher's exact test. The odds ratio (OR) for the frequency of pattern B phenotype was calculated with Cochran-MantelHaenzel statistics.
Results
Interrelations between lipid parameters
The relationships between LDL size and serum TG, LDL size and serum HDL-C, and serum TG and HDL-C for the two different LDL size classes in all subjects are shown in Figure 1 . Diameters of the predominant LDL particles in all subjects correlated negatively with TG concentration (r = -0.558, p<0.001) (Figure 1a ) and positively with HDL-C (r = 0.471, p<0.001) (Figure 1b) . In addition, diameters of the predominant LDL particles in all subjects were associated positively with levels of apo A-I (r = 0.289, p<0.001) and negatively with levels of apo B (r = -0.290, p<0.001) (data not shown). The major proportion of subjects with LDL diameter < 25.5 nm had HDL-C ≤ 0.91 mmol/l and TG > 1.65 mmol/l (Figure 1c) .
Characterization of patient groups
Age-adjusted lipid profiles of the four groups are summarized in Table 1 . Except for apo A-I in group 1, apo B and LDL size in group 3, LDL-C for women in group 1 and for men in group 3, significant differences for other lipid parameters were observed between the control group and patient groups.
Significant sex differences were not seen in LDL size in any of the four groups ( Table 1 ). The predominant LDL particles in groups 1 and 2 were significantly smaller than those in the control group. However, no significant differences in LDL size were observed between the control group and group 3. The mean LDL size was smallest in group 2. Moreover, small, dense LDL area (%) was significantly greater in group 2 than in the control group, group 1 or group 3 (Table 1) . No significant differences in small, dense LDL area (%) were observed between the control group and group 1 and group 3.
Frequency of LDL phenotype
The number of subjects in the control group and in the groups with abnormal lipid profiles, either of pattern A or pattern B LDL phenotypes, are shown in Table 2 . All subjects in the control group displayed pattern A phenotype. Pattern B phenotype was recognized in three of 36 subjects (8.3%) in group 1, 62 of 106 subjects (58.8%) in group 2, and three of 27 (11.1%) in group 3. Differences in the frequency of the pattern B phenotype between group 2 and either group 1 or group 3 were clearly demonstrated by chi-square analysis (group 2 vs. group 1: chi-square =39.45, p<0.005; group 2 vs. group 3: chi-square = 19.30, p<0.005). OR for group 2 with pattern B phenotype compared with group 1 and group 3 was 7.0 [95% confidence interval (CI), 2.01 to 24.05)] and OR 5.3 (95% CI, 1.52 to 18.92), respectively. These significant differences were not changed even if subjects taking lipid-lowering drugs were excluded (data not shown). The relations between the percentage of small, dense LDL to the total LDL and the frequency in subjects having that percentage of small, dense LDL is shown for each group in Figure 2 . For all three levels of small, dense LDL described in Figure 2 , the frequency of each in group 2 was significantly greater than in the control group. No significant differences were observed between the control group and both group 1 and group 3. 
LDL phenotype and LPL gene mutations
Of the 106 subjects in group 2, 33 were found to have LPL gene mutation. LPL genotype and LPL mass in 33 subjects are shown in Table 3 . In these subjects, six different mutations were found in four exons and one intron of the LPL gene. Mutations of exon 3 (Tyr61Ter), intron 3 (-6C→T), and exon 9 (Ser447Ter) have been reported elsewhere (13, 17, 18) . Mutation of exon 7 (Ser323Cys) was identified in our previous study (19) . Mutations of exon 3 (Glu62Asp) and exon 6 (Ala261Thr) in combination with exon 7 (Ser323Cys) are novel and are reported here. Nine subjects with mutations including exon 3 (Tyr61Ter), exon 3 (Glu62Asp), intron 3 (-6C→T), and exon 6 (Ala261Thr) in combination with exon 7 (Ser323Cys), and solitary exon 7 (Ser323Cys) mutation, not only expressed pattern B, but also showed low pre-heparin LPL mass. Twenty-four subjects had an exon 9 (Ser447Ter) mutation, 6 homozygous and 18 heterozygous. Of the 24 subjects with the exon 9 (Ser447Ter) mutation, 12 exhibited pattern B phenotype, including six subjects homozygous for the exon 9 (Ser447Ter) mutation. The other 12 subjects displayed pattern A phenotype. All subjects with an exon 9 mutation had normal pre-heparin LPL mass.
Lipid parameters and LDL phenotype in subjects with or without LPL gene mutations
Except for pre-heparin LPL mass, lipid parameters including LDL size and mean percentage of small, dense LDL area (%) did not differ significantly between subjects with and without LPL gene mutation (data not shown). For further analysis, we excluded the 24 subjects with the exon 9 (Ser447Ter) mutation because it is Tab. 1 Serum lipid and lipoprotein concentrations in the studied patient groups. whether this mutation decreases LPL activity. Nine subjects with LPL mutations remained, eight men and one women. The number of women was too small for statistical analysis. The means of age-adjusted TG and apo B were significantly higher in men with the mutation than in those without (p<0.05, p<0.05, respectively) ( Table 4 ). In contrast, the mean LDL size in men with the mutation was significantly decreased compared to men without the mutation (p<0.05). The subjects with LPL mutations other than exon 9 (Ser447Ter) also showed a significant increase in pattern B phenotype (Table 5 ).
Tab. 3 LDL phenotype in subjects with LPL gene mutations.
Mutation site Pre-heparin LPL mass b LPL genotype LDL phenotype (µg/l) (n) (n) 
Discussion
Hypertriglyceridemia is characterized by a diverse plasma lipid profile, including elevated apo B, reduced apo A-I, decreased or normal HDL-C, and increased small, dense LDL. A previous study showed TG concentration correlates negatively with LDL size (20) . Hall et al. showed that subjects with dyslipoproteinemia and HDL-C concentrations < 0.91 mmol/l had increased plasma small, dense LDL and apo B concentrations (21) . We observed similar associations between LDL size and concentrations of TG and HDL-C (r = -0.558, r = 0.471, respectively). In particular, we observed a higher proportion of LDL phenotype B in hypertriglyceridemic subjects with LDL particle size less than 25.5 nm and low HDL-C. Moreover, we also found that high TG and low HDL-C levels can be accompanied by quantitatively higher levels of small, dense LDL . In general, very low density lipoprotein (VLDL) and chylomicrons are delipidated by the action of LPL and hepatic triglyceride lipase (HTGL) and ultimately produce TG-poor and cholesterol-rich LDL or normal LDL. Several investigations have hypothesized that cholesteryl ester transfer protein (CETP) plays an important role in the formation of small, dense LDL (22) (23) (24) (25) (26) (27) . Briefly, when TG-rich lipoprotein (VLDL, chylomicrons) concentration increases (plasma TG > 1.55 mmol/l), the activity of CETP increases (27) . The exchange of cholesteryl ester and TG between LDL, and VLDL or chylomicrons is promoted by CETP, generating TG-rich LDL. TG-rich LDL then serves as a substrate for both LPL and HTGL and leads to the production of small, dense LDL. Therefore, excess of small, dense LDL may easily form when a high plasma TG level is accompanied by low HDL-C, since the low HDL concentration may have too little cholesteryl ester to transfer to LDL. Under conditions where a high plasma TG level accompanies normal HDL-C level, less small, dense LDL may form because the exchange of cholesteryl ester and TG favors the reaction between TG-rich lipoprotein and HDL. In our experiment, increased frequency of pattern B phenotype and higher concentrations of small, dense LDL occurred exclusively in hypertriglyceridemic subjects with plasma HDL-C at concentrations ≤ 0.91 mmol/l. In contrast, it may be difficult to produce small, dense LDL in serum with normal TG and HDL-C levels ≤ 0.91 mmol/l because the system of exchange between LDL and TG-rich lipoprotein is inactive. We also noticed that pattern B phenotype and higher concentrations of small, dense LDL in serum are not usually observed in individuals with normal TG and HDL-C levels ≤ 0.91 mmol/l or normal TG and HDL-C levels ≥ 1.17 mmol/l. Thus, LPL activity should play an important role in the formation of small, dense LDL.
LPL deficiency is one cause of familial hypertriglyceridemia. In a previous study, we found that subjects with both high TG and low HDL-C (≤ 0.91 mmol/l) levels show high frequency of LPL gene mutations (19) . The lipid profiles we observed were quite similar to those in the group with high TG and low HDL-C, which correlates with high serum small, dense LDL. LPL has two structurally distinct regions consisting of an amino-terminal domain (residues 1-312) and carboxyl-terminal end (residues 313-448). The catalytic function is located in the amino-terminal domain of LPL. The carboxyl-terminus of LPL appears to play a major role in the initial interaction of LPL with lipoproteins, which is necessary for subsequent hydrolysis of circulating plasma TG (28) . Previous studies showed that mutations of both exon 3 (Tyr61Ter) and exon 6 (Ala261Thr) lead to LPL deficiency, resulting in high plasma TG and low HDL-C levels (12, 29) . LPL intron 3 (-6 C→T) is thought to associate with lower LPL mRNA promoter efficacy (17) . In our study, subjects with mutations that affected the catalytic domain of LPL or resulted in lower promoter efficacy, such as exon 3 (Glu62Asp), exon 6 (Ala261Thr) in combination with exon 7 (Ser323Cys), and intron 3 (-6 C→T), displayed not only low amounts of pre-heparin LPL mass in serum but also pattern B phenotype. Mutation of exon 3 (Glu62Asp) or exon 7 (Ser323Cys) seems to be associated with decreased LPL activity, subjects with these mutations being accompanied by low level of pre-heparin LPL mass. These subjects also expressed pattern B phenotype. Thus, it is possible that these mutations are associated with the formation of small, dense LDL. Furthermore, 24 subjects with mutation in exon 9 (Ser447Ter) had normal pre-heparin LPL mass. The incidence of exon 9 (Ser447Ter) mutation in the healthy Japanese subjects was 21.0% (30) . The role of this genotype in the plasma lipid levels has been investigated by several authors who obtained discordant results. Some reported that exon 9 (LPL Ser447Ter) mutation is not significantly associated with a decrease in LPL activity (31, 32) or is associated with high levels of HDL-C (33). Others reported an association between exon 9 (Ser447Ter) mutation with hypertriglyceridemia (34) . As in the present study subjects homozygous and heterozygous for exon 9 (Ser447Ter) mutation displayed different LDL phenotype, it is necessary to further investigate whether the allele frequency for exon 9 (Ser447Ter) mutation is associated with the LDL phenotype.
Conclusion
When subjects with pattern B phenotype were grouped according to the levels of serum TG and HDL-C, we found that this phenotype existed almost entirely in subjects with hypertriglyceridemia in combination with HDL-C levels ≤ 0.91 mmol/l. We also found that there was a quantitatively higher concentration of small, dense LDL in hypertriglyceridemic subjects with HDL-C levels ≤ 0.91 mmol/l. We conclude that pattern B phenotype is associated with some LPL gene mutations that may decrease LPL activity
